What is the Rhythm Pharmaceuticals Inc. stock price forecast?

Rhythm Pharmaceuticals Inc. is currently trading at $89.72. View real-time AI analysis on Alpha Lenz.

What is Rhythm Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Rhythm Pharmaceuticals Inc. on Alpha Lenz.

What is Rhythm Pharmaceuticals Inc.'s P/E ratio?

Rhythm Pharmaceuticals Inc.'s P/E ratio is -29.7.

Rhythm Pharmaceuticals Inc.

NASDAQ · RYTM

$89.72+0.02(+0.02%)Pre-market

Ask about Rhythm Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Rhythm Pharmaceuticals Inc. trades at a P/E of -29.7 (undervalued) with modest ROE of -90.5%. 3Y revenue CAGR of 100.2% highlights clear growth momentum.”

Ask for details →

Company Overview

Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for rare genetic disorders of obesity. The company’s flagship product, Setmelanotide, targets the melanocortin-4 receptor (MC4R) pathway, which is crucial in regulating hunger, energy expenditure, and body weight. Rhythm Pharmaceuticals aims to address the underlying causes of obesity in patients with these genetic conditions, offering a more personalized approach to treatment compared to traditional weight management solutions. Primarily impacting the healthcare and biotechnology sectors, Rhythm’s innovations are significant to the advancement of precision medicine, particularly within the growing field of genetic-based therapies. Their dedication to research and development highlights the crucial role they play in addressing unmet medical needs. Headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals not only contributes to scientific progress but also has the potential to improve the quality of life for patients suffering from complex and often misunderstood health issues related to genetic obesity disorders.

CEODr. David P. Meeker M.D.

Websitehttps://rhythmtx.com

SectorHealthcare

IndustryBiotechnology

Employees283

Company Statistics

FY 2025

Profile

$5.83BMarket Cap

$189.76MRevenue

0.00Shares Out

283Employees

Margins

89.73%Gross

-91.76%EBITDA

-101.19%Operating

-103.31%Pre-Tax

-103.57%Net

Valuation

-29.67P/E

21.59P/B

30.73EV/Sales

-33.20EV/EBITDA

-49.99P/FCF

Growth (CAGR)

100.23%Rev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-45.05%ROA

-90.45%ROE

-40.22%ROIC

Financial Health

$54.30MCash & Cash Equivalents

$155.87MNet Debt

77.83%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Rhythm Pharmaceuticals Inc. trades at a P/E of -29.7 (undervalued) with modest ROE of -90.5%. 3Y revenue CAGR of 100.2% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Rhythm Pharmaceuticals Inc. (ticker: RYTM) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 283 employees. Market cap is $5.8B.

The current price is $89.72 with a P/E ratio of -29.67x and P/B of 21.59x.

ROE is -90.45% and operating margin is -101.19%. Annual revenue is $190M.